Previous studies showed that transformation agents such as histone deacetylase inhibitors, multi-kinase inhibitors, and bone morphogenetic proteins (BMPs) can revert GBM cells to their glial origins or to other glial cell types such as oligodendrocytes [32,52,53,54,55,56]. Here, CLN5 is linked to glioblastoma.